Free tool
FAERS Monitor: Travatan Z
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021994 or its brand name (Travatan Z, Travoprost). Reports on generic versions are filed under their own applications.
Reports
8,671
Serious
3,182
37% of reports
Hospitalization
1,143
Death reported
333
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- treatment failure1,951
- drug ineffective545
- ocular hyperaemia503
- eye irritation499
- eye pain352
- intraocular pressure increased299
- hypersensitivity269
- fatigue268
- glaucoma260
- headache237
- dizziness236
- vision blurred236
- visual impairment226
- death208
- dyspnoea206
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 16 |
| 2005 | 47 |
| 2006 | 32 |
| 2007 | 35 |
| 2008 | 37 |
| 2009 | 55 |
| 2010 | 68 |
| 2011 | 85 |
| 2012 | 114 |
| 2013 | 113 |
| 2014 | 164 |
| 2015 | 361 |
| 2016 | 633 |
| 2017 | 821 |
| 2018 | 792 |
| 2019 | 743 |
| 2020 | 2,608 |
| 2021 | 483 |
| 2022 | 355 |
| 2023 | 291 |
| 2024 | 253 |
| 2025 | 325 |
| 2026 | 240 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,488 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| treatment failureSignal | 1,951 | 58.5 | 56.2 | 107,996 |
| intraocular pressure increasedSignal | 299 | 58.1 | 51.9 | 16,337 |
| glaucomaSignal | 260 | 33.2 | 29.4 | 7,983 |
| ocular hyperaemiaSignal | 503 | 26.0 | 23.8 | 11,952 |
| eye irritationSignal | 499 | 21.2 | 19.5 | 9,529 |
| eye painSignal | 352 | 15.2 | 13.7 | 4,647 |
| visual impairmentSignal | 226 | 4.4 | 3.9 | 599 |
| vision blurredSignal | 236 | 4.2 | 3.7 | 569 |
| hypersensitivitySignal | 269 | 3.5 | 3.1 | 486 |
| dizziness | 236 | 1.1 | 1.0 | 4 |
| drug ineffective | 545 | 1.0 | 0.9 | 0 |
| headache | 237 | 0.9 | 0.8 | 2 |
| dyspnoea | 206 | 0.9 | 0.8 | 3 |
| fatigue | 268 | 0.8 | 0.7 | 9 |
| death | 208 | 0.6 | 0.5 | 63 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.